Literature DB >> 33784013

LAG3 and its emerging role in cancer immunotherapy.

Miao Wang1, Qi Du1, Jiangtao Jin2, Yuhan Wei1, Yuting Lu1, Qin Li1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33784013      PMCID： PMC7989707          DOI： 10.1002/ctm2.365

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  10 in total

1.  LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII.

Authors:  Takumi Maruhashi; Il-Mi Okazaki; Daisuke Sugiura; Suzuka Takahashi; Takeo K Maeda; Kenji Shimizu; Taku Okazaki
Journal:  Nat Immunol       Date:  2018-10-22       Impact factor: 25.606

2.  MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

Authors:  Patrice Hemon; Francette Jean-Louis; Kiran Ramgolam; Chrystelle Brignone; Manuelle Viguier; Hervé Bachelez; Frédéric Triebel; Dominique Charron; Fawzi Aoudjit; Reem Al-Daccak; Laurence Michel
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

3.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Authors:  Jun Wang; Miguel F Sanmamed; Ila Datar; Tina Tianjiao Su; Lan Ji; Jingwei Sun; Ling Chen; Yusheng Chen; Gefeng Zhu; Weiwei Yin; Linghua Zheng; Ting Zhou; Ti Badri; Sheng Yao; Shu Zhu; Agedi Boto; Mario Sznol; Ignacio Melero; Dario A A Vignali; Kurt Schalper; Lieping Chen
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

4.  LAG-3: another brake to release in breast cancer?

Authors:  M Kok
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

Review 5.  Immune checkpoint inhibitors: The linchpins of modern immunotherapy.

Authors:  Breelyn A Wilky
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

Review 6.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 7.  Emerging targets in cancer immunotherapy.

Authors:  Samantha Burugu; Amanda R Dancsok; Torsten O Nielsen
Journal:  Semin Cancer Biol       Date:  2017-10-05       Impact factor: 15.707

Review 8.  Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.

Authors:  Edo Kon; Itai Benhar
Journal:  Drug Resist Updat       Date:  2019-07-29       Impact factor: 18.500

Review 9.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.

Authors:  Shuang Qin; Linping Xu; Ming Yi; Shengnan Yu; Kongming Wu; Suxia Luo
Journal:  Mol Cancer       Date:  2019-11-06       Impact factor: 27.401

Review 10.  LAG-3: from molecular functions to clinical applications.

Authors:  Takumi Maruhashi; Daisuke Sugiura; Il-Mi Okazaki; Taku Okazaki
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751
  10 in total
  14 in total

1.  LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.

Authors:  Ying Liu; Xinhong Guo; Lingbo Zhan; Lei Wang; Xinyou Wang; Ming Jiang
Journal:  Comput Math Methods Med       Date:  2021-08-12       Impact factor: 2.238

2.  Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism.

Authors:  Miao Wang; Yuhan Wei; Yingrui Li; Hongzhong Li; Jiangtao Jin; Yuting Lu; Qin Li
Journal:  Immun Inflamm Dis       Date:  2022-08

3.  A Four-Gene Prognostic Signature Based on the TEAD4 Differential Expression Predicts Overall Survival and Immune Microenvironment Estimation in Lung Adenocarcinoma.

Authors:  Xiaoxia Gong; Ning Li; Chen Sun; Zhaoshui Li; Hao Xie
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

Review 4.  Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.

Authors:  Szonja Anna Kovács; Balázs Győrffy
Journal:  J Transl Med       Date:  2022-05-31       Impact factor: 8.440

Review 5.  Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma.

Authors:  Pablo Álvarez Ballesteros; Jesús Chamorro; María San Román-Gil; Javier Pozas; Victoria Gómez Dos Santos; Álvaro Ruiz Granados; Enrique Grande; Teresa Alonso-Gordoa; Javier Molina-Cerrillo
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

Review 6.  From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.

Authors:  Jonathan Anker; Justin Miller; Nicole Taylor; Natasha Kyprianou; Che-Kai Tsao
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

Review 7.  Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.

Authors:  Yuting Lu; Xiangliang Yuan; Miao Wang; Zhihao He; Hongzhong Li; Ji Wang; Qin Li
Journal:  J Hematol Oncol       Date:  2022-04-29       Impact factor: 23.168

Review 8.  Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.

Authors:  An-Ping Shi; Xi-Yang Tang; Yan-Lu Xiong; Kai-Fu Zheng; Yu-Jian Liu; Xian-Gui Shi; Yao Lv; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561

9.  Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome.

Authors:  Elisa Ciraolo; Stefanie Althoff; Josefine Ruß; Stanislav Rosnev; Monique Butze; Miriam Pühl; Marco Frentsch; Lars Bullinger; Il-Kang Na
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

10.  The role of YTH domain containing 2 in epigenetic modification and immune infiltration of pan-cancer.

Authors:  Chiyuan Zhang; Cuishan Guo; Yan Li; Ling Ouyang; Qi Zhao; Kuiran Liu
Journal:  J Cell Mol Med       Date:  2021-07-27       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.